Komori
Statutory disclosure document4572Carna Biosciences,Inc.Pharmaceuticals

Report on the Transfer of Shares Issued Through a Third-Party Allotment (New Shares)

Of the shares issued through a third-party allotment on 11 October 2024, 434,200 shares were transferred from Athos Asia Event Driven Master Fund to Macquarie Bank Limited in an off-auction transaction. It is explained that the original allottee continues to enjoy the economic gains and losses on the shares after the transfer.

Worth reading
59In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
434200
Shares
Wording
Definitive
How definitive the wording is.

Decision and Details

Transfer of shares allotted through a third-party allotment

Implementation11 May 2026 (actual)
AmountTransfer price: ¥461 per share
Quantity / scaleNumber of shares transferred: 434,200 shares; number of shares allotted: 1,050,600 shares; cumulative number of shares transferred: 1,050,600 shares (as of 11 May 2026)
Reason

The shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to enjoy the economic gains and losses from these shares after the transfer.

Decision and Details
ItemDetails
Matter CoveredTransfer of shares allotted through a third-party allotment
Implementation Date11 May 2026 (actual)
AmountTransfer price: ¥461 per share
Quantity / scaleNumber of shares transferred: 434,200 shares; number of shares allotted: 1,050,600 shares; cumulative number of shares transferred: 1,050,600 shares (as of 11 May 2026)
ReasonThe shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to enjoy the economic gains and losses from these shares after the transfer.
Related previous disclosuresShares of the Company allotted through a third-party allotment on 11 October 2024
Items this document does not state (6)
Decision-Making BodyDecision DatePeriod CoveredImpact on Business PerformanceGoverning RuleFuture plans

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because the shares were transferred to a swap position. Athos Asia Event Driven Master Fund continues to enjoy the economic gains and losses from these shares after the transfer.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on the Transfer of Shares Issued Through a Third-Party Allotment (New Shares) | Carna Biosciences,Inc. (4572) timely disclosure | Komori